research Archives - Page 3 of 7

Home
/
Projects
/

research

The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug resistant tuberculosis in India and China

2021

We investigated the epidemiologic impact, cost-effectiveness, and budget impact of hypothetical novel prophylactic prevention of disease TB vaccines on RR/MDR-TB in China and India.

An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines

2023

Completed

Understanding public willingness to receive new TB vaccines, as well as defining how to address any barriers to acceptance, will be key to ensuring that the promise of these vaccines can be fully realized. Although we can learn from previous vaccine intro ductions, it is imperative we close key research gaps specific to new TB vaccines. This will inform the development of interventions to generate and sustain high demand for TB vaccines in communities that stand to benefit the most

Potential impact of spatially targeted adult tuberculosis vaccine in Gujarat, India

2016

Hypothetical vaccines

Completed

we aimed to estimate the impact of vaccine delivery strategies that were targeted to high-incidence geographical 'hotspots' compared with randomly allocated vaccination. We developed a spatially explicit mathematical model of TB transmission that distinguished these hotspots from the general population.

Modelling impact of TB vaccination vs other interventions/policies

2023

Ongoing

Creating evidence to support tuberculosis decision-makers in reducing the global burden of Tuberculosis

The health and economic benefits possible with novel tuberculosis vaccines – A modeling study in India and Indonesia

2021

M72/AS01e

Completed

We estimated gains possible with novel post-exposure vaccines, in India and Indonesia. We modeled vaccine impact on TB incidence, TB mortality, and on national income growth and the intrinsic value of living longer, known as Full-income.

Epidemiologic study to assess the IGRA positivity in populations with a high TB

2021 - 2024

M72/AS01e

Ongoing

Tuberculosis (TB) vaccine efficacy trials evaluating prevention of disease must be feasible in size and duration and would ideally take place at clinical trial sites that enroll from communities with the highest incidence rates. In preparation for the Phase 3 trial of the investigational M72/AS01E-4 vaccine, we conducted a multi-country study, using interferon gamma release assay (IGRA) positivity as a proxy for expected incidence of TB. In addition to the above objects, the results from this study could help in in new vaccine introduction to identfy TB hotspot areas.

Making wider use of the world’s most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered

2013

BCG revaccination

Completed

This paper assesses the effectiveness and cost-effectiveness of revaccinating adolescents in a setting with intense transmission—Cape Town, South Africa.

Mixed vaccination strategy for the control of tuberculosis: A case study in China

2017

Hypothetical vaccines

Completed

This study first presents a mathematical model of TB transmission considering BCG vaccination compartment to investigate the transmission dynamics nowadays

New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01E and BCG-revaccination

2023

BCG revaccination, M72/AS01e

Completed

We estimated the potential health and economic impact of M72/AS01E and BCG-revaccination in India and investigated the impact of variation in vaccine characteristics and delivery strategies.

Epidemiological impact of targeted interventions for people with diabetes mellitus on tuberculosis transmission in India: Modelling based predictions

2020

Hypothetical vaccines

Completed

We aimed to assess the impact on TB disease of several intervention strategies targeting people with DM in India.